Results 101 to 110 of about 59,768 (257)
The Journal of Dermatology, EarlyView.ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe +4 more
wiley +1 more source
Australasian Journal of Dermatology, EarlyView.ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim +7 more
wiley +1 more source
Australasian Journal of Dermatology, EarlyView.ABSTRACT Dupilumab‐associated erythema multiforme and lichenoid eruptions have been previously reported as rare dermatological adverse events. We present an atypical paediatric case of a dupilumab‐associated erythema multiforme‐like eruption in a 5‐year‐old male eczema patient, who developed erythematous targetoid papules and plaques over the upper and
Paul Sun Woo Kim +7 more
wiley +1 more source
Allergy, EarlyView.Three molecular profiles identified among Art v 1/Amb a 4‐sensitized patients: Art v 1 monosensitization, Amb a 4 monosensitization, and dual sensitization to both allergens. Art v 1 monosensitization was predominantly associated with allergic rhinitis, reflecting a classical airborne allergy pattern.
Enrico Scala +20 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source
Allergy, EarlyView.This study established a microarray containing a representative panel of purified Blo t and Der p allergens for the identification of patients sensitised to Blo t and/or Der p. Results indicate that the microarray based on Blo t and Der p allergens is a useful tool for the identification of Blo t‐ and/or Der p‐sensitised patients. The microarray may be
Nishelle Dsouza +16 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
Allergy, EarlyView.We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
Allergy, EarlyView.We exposed human nasal epithelial tissues to pollen from grasses grown under different climate treatments (temperature and CO2). Pollen weakened epithelial tight junctions and altered cytokine‐related gene expression, with similar protein‐level effects.
Tarleena Tossavainen +5 more
wiley +1 more source
Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema
Allergy, EarlyView.This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery +25 more
wiley +1 more source